Crescent Biopharma Receives Regulatory Clearances to Begin Clinical Trials for Two Novel Cancer Therapies

Crescent Biopharma, Inc. (Nasdaq: CBIO), a clinical‑stage biotechnology company focused on advancing new cancer treatments, announced that regulatory authorities have cleared Investigational New Drug (IND) applications for two of its experimental therapies targeting solid tumors. The U.S. **Food and Drug Administration (FDA)** has cleared Crescent’s IND for **CR‑001**, a PD‑1 × VEGF bispecific antibody designed to both enhance immune response and block tumor blood vessel growth. Meanwhile, Crescent’s partner **Sichuan Kelun‑Biotech** received IND approval from China’s **National Medical Products Administration (NMPA)** for **CR‑003** (also known as SKB105), an antibody‑drug conjugate (ADC) targeting integrin beta‑6 (ITGB6). Crescent plans a global Phase 1/2 clinical trial called ASCEND for CR‑001, expected to start in the first quarter of 2026 and enroll up to 290 patients with various solid tumors, including non‑small cell lung cancer and gastrointestinal and gynecological cancers. Proof‑of‑concept data from this trial are anticipated in the first quarter of 2027. Under a strategic collaboration announced in late 2025, Crescent holds rights to develop and commercialize CR‑003 outside Greater China, while Kelun‑Biotech holds rights in Greater China. Crescent expects four clinical trials across its oncology portfolio to launch in 2026. #CrescentBiopharma #CancerResearch #ClinicalTrials #BiotechInnovation #SlimScan #GrowthStocks #CANSLIM